KT-621 Data Provide Validation and Derisk Future Clinical Trials
                                                                                                  Relieves allergic rhinitis
        Preclinical                             In Humans                                        symptoms (TNSS, RQLQ)


POTENCY                                       Blocks Type 2 inflammation in
• < 100 pM DC90 in all relevant human cell     skin and impacts AD lesions
  types                                         (EASI, vIGA-AD, and skin                             Deep STAT6 degradation
                                                 transcriptomic changes)                                >94/95% in HV &
                                                                                                     patients with AD in skin
EFFICACY
• Blocked IL-4 and IL-13 signaling in human
  cells and in vivo systems equally or more
  potently than dupilumab                      Deep STAT6 degradation
                                              >95% in HV & patients with
• Robust activity in asthma and AD in                AD in blood
  mouse models
SAFETY                                                                                                 Robust and consistent
                                                                                                     reductions in itch (PPNRS,
• No AEs at any doses in:                                                                               SCORAD Itch, IL-31)
  • 4 weeks rat and NHP GLP tox
                                                                  Blocks Type 2 inflammation
  • 4 months rat and NHP GLP tox
                                                                  in lungs (FeNO) and relieves
  • Embryofetal development tox in rat,                            asthma symptoms (ACQ-5)
    rabbit and NHP
                                                                                                                                  18
